Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Sera Prognostics, Inc.NASDAQ: SERA

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI falls 78.9% from a year ago

Accumulated OCI stood at $16K at the end of Q1 FY2026, down 78.9% from a year earlier and down 93.9% from the prior quarter.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -78.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16K-93.9% QoQ
Last fiscal yearDec 2025
$262K+336.7% YoY
Year agoMar 2025
$76K-78.9% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-78.9%——
1 year+336.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
262K USD
Year-over-year change
+336.7%

Accumulated OCI vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -78.9% is the 3rd highest of 5, against a peer median of +0.0%.
  • Accumulated OCI amounts to 0.0% of total assets for SERA, versus a peer median of 0.0%.
SERA Competitors
Accumulated OCI for SERA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ONCYOncolytics Biotech Inc.Mar 2026CA$6.23M CAD+549.8%+134.5%76.3%
SERASera Prognostics, Inc.Mar 2026$16K USD-78.9%—0.0%
SRZNSurrozen, Inc.Mar 2026$0 USD——0.0%
APYXApyx Medical CorporationMar 2026$0 USD——0.0%
HURATuHURA Biosciences, Inc.Mar 2026$0 USD+100.0%—0.0%
LUCDLucid Diagnostics Inc.Mar 2026$0 USD——0.0%
CGTXCognition Therapeutics, Inc.Mar 2026$0 USD——0.0%
STSSSkyAI, Inc.Mar 2026$0 USD-100.0%—0.0%
RPIDRapid Micro Biosystems, Inc.Mar 2026-$1K USD-107.7%—0.0%
Peer median (excluding SERA) —+0.0%+134.5%0.0%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents58.93M29.88M3.88M4.04M3.94M
Short-term Investments46.18M52.83M45.2M42.19M35.26M
Net Receivables3.14M6.11M11.47M34K12K
Inventory00000
Other Current Assets1.99M1.31M795K19K1.56M
Total Current Assets110.25M90.13M61.34M47.6M40.77M
Property, Plant & Equipment (Net)1.77M3.06M3.18M1.85M3.55M
Goodwill00000
Intangible Assets0001.03M910K
Long-term Investments34.85M21.33M30.84M21.97M56.58M
Tax Assets00000
Other Non-current Assets157K1.82M77K124K123K
Total Non-current Assets36.78M26.2M34.1M24.98M61.16M
Total Assets147.03M116.33M95.44M72.58M101.93M
Account Payables1.2M1.55M1.05M1.97M862K
Short-term Debt00000
Tax Payables00000
Deferred Revenue3.12M9.08M20.24M20.22M20.32M
Other Current Liabilities3.56M1.07M926K20.52M3.01M
Total Current Liabilities8.41M15.54M24.44M24.77M24.19M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities54K1.85M840K2K2.34M
Total Liabilities8.47M17.39M25.28M24.77M26.53M
Common Stock3K3K3K3K4K
Retained Earnings(166.47M)(210.65M)(246.9M)(279.79M)(311.72M)
Accumulated OCI(183K)(981K)(15K)60K262K
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity138.56M98.94M70.16M47.8M75.41M
Total Debt128K2.83M1.86M840K2.34M
Net Debt(58.8M)(27.05M)(2.02M)(3.2M)(1.61M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.